NR566 EXAM SCRIPT FINAL PAPER 2026
FULL SOLUTION VIEW AHEAD
◉ Clindamycin Antimicrobial Spectrum.
Answer: active against most anaerobic bacteria (gram-positive and
gram-negative) and most gram-positive aerobes; Gram-negative
aerobes are generally resistant.
Bacteroides fragilis, Fusobacterium species, Clostridium perfringens,
and anaerobic streptococci
◉ Clindamycin Main Adverse Event.
Answer: CDAD, formerly known as antibiotic-associated
pseudomembranous colitis, is the most severe toxicity associated
with this ABX
◉ Clindamycin Therapeutic Use.
Answer: -Effective against gram-positive cocci;
-Widely used as an alternative to penicillin
,-Employed primarily for anaerobic infections outside the CNS and is
the drug of choice for severe group A streptococcal infection and for
gas gangrene (an infection caused by C. perfringens)
◉ Clindamycin Black Box Warning.
Answer: Can cause potentially fatal Clostridium difficile diarrhea.
Patients should promptly report any diarrhea to their health care
provider.
◉ Patients with creatinine clearance <30mL/min.
Answer: Avoid ciprofloxacin and nitrofurantoin
◉ Patients concurrently prescribed warfarin.
Answer: avoid trimethoprim/sulfamethoxazole, macrolides, and
ciprofloxacin
◉ ABX prescribed safely throughout pregnancy.
Answer: Penicillins, cephalosporins, and erythromycin
◉ ABX avoided throughout pregnancy.
Answer: Fluoroquinolones should be avoided due to potential
cartilage damage risk.
Tetracyclines should be avoided due to potential tooth damage and
staining.
,◉ Aminoglycoside MOA.
Answer: disrupt bacterial protein synthesis; bind to the 30S
ribosomal subunit, causing;
(1) inhibition of protein synthesis
(2) premature termination of protein synthesis
(3) production of abnormal proteins (secondary to misreading of the
genetic code).
◉ Bactericidal effects of the aminoglycosides.
Answer: limited almost exclusively to aerobic gram-negative bacilli;
inactive against most gram-positive bacteria.
◉ Aminoglycoside Therapeutic Goal.
Answer: Treatment of serious infections caused by gram-negative
aerobic bacilli.
-Requires 02 for uptake;
*INEFFECTIVE AGAINST ANAEROBIC BACTERIA*
◉ Aminoglycoside Black Box Warning.
Answer: -associated with irreversible ototoxicity. Neurotoxic
symptoms may also include numbness, tingling, muscle twitching,
and seizures.
, -associated with nephrotoxicity.
-can inhibit neuromuscular transmission, causing flaccid paralysis
and potentially fatal respiratory depression
-risk increased in patients on high doses or with prolonged use;
patients with preexisting renal impairment.
◉ Aminoglycoside Monitoring.
Answer: Drug levels (peaks and troughs) and renal function must be
monitored.
◉ Aminoglycoside High Risk Patients.
Answer: used with caution in patients with renal impairment,
preexisting hearing impairment, and those receiving ototoxic and
nephrotoxic drugs.
◉ Gentamicin Indication (Aminoglycoside).
Answer: Bacterial infections caused by aerobic gram-negative bacilli:
Pseudomonas aeruginosa; Enterobacteriaceae
◉ Aminoglycoside Contraindication.
Answer: risk for injury to the inner ears is increased by concurrent
use of loop diuretics—these combinations should be avoided.
◉ Sulfonamide MOA.
FULL SOLUTION VIEW AHEAD
◉ Clindamycin Antimicrobial Spectrum.
Answer: active against most anaerobic bacteria (gram-positive and
gram-negative) and most gram-positive aerobes; Gram-negative
aerobes are generally resistant.
Bacteroides fragilis, Fusobacterium species, Clostridium perfringens,
and anaerobic streptococci
◉ Clindamycin Main Adverse Event.
Answer: CDAD, formerly known as antibiotic-associated
pseudomembranous colitis, is the most severe toxicity associated
with this ABX
◉ Clindamycin Therapeutic Use.
Answer: -Effective against gram-positive cocci;
-Widely used as an alternative to penicillin
,-Employed primarily for anaerobic infections outside the CNS and is
the drug of choice for severe group A streptococcal infection and for
gas gangrene (an infection caused by C. perfringens)
◉ Clindamycin Black Box Warning.
Answer: Can cause potentially fatal Clostridium difficile diarrhea.
Patients should promptly report any diarrhea to their health care
provider.
◉ Patients with creatinine clearance <30mL/min.
Answer: Avoid ciprofloxacin and nitrofurantoin
◉ Patients concurrently prescribed warfarin.
Answer: avoid trimethoprim/sulfamethoxazole, macrolides, and
ciprofloxacin
◉ ABX prescribed safely throughout pregnancy.
Answer: Penicillins, cephalosporins, and erythromycin
◉ ABX avoided throughout pregnancy.
Answer: Fluoroquinolones should be avoided due to potential
cartilage damage risk.
Tetracyclines should be avoided due to potential tooth damage and
staining.
,◉ Aminoglycoside MOA.
Answer: disrupt bacterial protein synthesis; bind to the 30S
ribosomal subunit, causing;
(1) inhibition of protein synthesis
(2) premature termination of protein synthesis
(3) production of abnormal proteins (secondary to misreading of the
genetic code).
◉ Bactericidal effects of the aminoglycosides.
Answer: limited almost exclusively to aerobic gram-negative bacilli;
inactive against most gram-positive bacteria.
◉ Aminoglycoside Therapeutic Goal.
Answer: Treatment of serious infections caused by gram-negative
aerobic bacilli.
-Requires 02 for uptake;
*INEFFECTIVE AGAINST ANAEROBIC BACTERIA*
◉ Aminoglycoside Black Box Warning.
Answer: -associated with irreversible ototoxicity. Neurotoxic
symptoms may also include numbness, tingling, muscle twitching,
and seizures.
, -associated with nephrotoxicity.
-can inhibit neuromuscular transmission, causing flaccid paralysis
and potentially fatal respiratory depression
-risk increased in patients on high doses or with prolonged use;
patients with preexisting renal impairment.
◉ Aminoglycoside Monitoring.
Answer: Drug levels (peaks and troughs) and renal function must be
monitored.
◉ Aminoglycoside High Risk Patients.
Answer: used with caution in patients with renal impairment,
preexisting hearing impairment, and those receiving ototoxic and
nephrotoxic drugs.
◉ Gentamicin Indication (Aminoglycoside).
Answer: Bacterial infections caused by aerobic gram-negative bacilli:
Pseudomonas aeruginosa; Enterobacteriaceae
◉ Aminoglycoside Contraindication.
Answer: risk for injury to the inner ears is increased by concurrent
use of loop diuretics—these combinations should be avoided.
◉ Sulfonamide MOA.
